Research programme: OX003R targeting monoclonal antibodies - Oxford BioTherapeutics
Alternative Names: Chimeric 1B3 antibody - Oxford BioTherapeutics; Chimeric anti-OX003R antibodies - Oxford BioTherapeutics; OX003R targeting antibodies - Oxford BioTherapeuticsLatest Information Update: 28 Sep 2024
At a glance
- Originator Oxford BioTherapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Colorectal cancer; Non-small cell lung cancer
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Breast-cancer in United Kingdom (Parenteral)
- 28 Sep 2024 No recent reports of development identified for preclinical development in Colorectal-cancer in United Kingdom (Parenteral)
- 28 Sep 2024 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in United Kingdom (Parenteral)